Phase 4 N=276 Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)
Chronic Liver Disease
Primary: PV Flow — 16.0; 15.5; 23.2; 27.1 ml/s
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=270 Liver Fibrosis Evaluation Using Ultrasound Shear Wave Imaging
Liver Fibrosis
Primary: Liver Stiffness Measured by MRE — 3.07 kPa
Phase 2 N=61 A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C
Hepatic Cirrhosis · Liver Fibrosis
Primary: The Number of Participants Who Achieve ≥ 1 Stage Improvement in Liver Fibrosis (METAVIR Score) as Determined by Liver Biopsy After 12 Weeks of Treatment — 3; 6; 2…
N/A N=1,061 Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages
Fatty Liver, Nonalcoholic · Diabetes Mellitus, Type 2
Primary: Action on Suspected Advanced Liver Fibrosis — 55; 4 Participants
N/A N=412 FibroTouch Non-invasive Evaluation of Liver Fibrosis and Cirrhosis
Liver Fibrosis · Cirrhosis · Chronic Hepatitis B
Primary: The Clinical Value Evaluation of FibroTouch for Non-invasive Diagnosis of Liver Fibrosis in Patients With Chronic Hepatitis B by Using Liver Pathology as the Gold…
N/A N=907 FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy
Cirrhosis · Hepatitis B · Hepatitis C
Primary: Diagnosis Performance of VCTE for Determination of Cirrhosis (Metavir F4) in Patients With Chronic Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) — 0.92 ROC area
N/A N=130 Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects
Cystic Fibrosis · Liver Fibrosis
Primary: Elastographic Value in kPa Measured by Fibroscan — 4.7 kPa
N/A N=180 Sonoelastography: Ultrasound Method to Measure Liver Fibrosis
Chronic Liver Disease · Non-Alcoholic Fatty Liver Disease · Hepatitis C Virus (HCV) Coinfection
Primary: Liver Elasticity Value Measured Using Sonoelastography (SE) — 7.225; 7.332; 8.548; 12.101 kilopascals (kPa)
N/A N=40 Noninvasive Biomarkers of Metabolic Liver Disease 1.1
Nonalcoholic Steatohepatitis · Nonalcoholic Fatty Liver
Primary: Evaluation of Pooled Different-day, Different-operator Reproducibility of Shear Wave Speed Measurements — 30.7 Reproducibility coefficient (in %)
Phase 2 N=197 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
Liver Fibrosis · Nonalcoholic Fatty Liver Disease (NAFLD) · Nonalcoholic Steatohepatitis
Primary: The Percentage of Participants With Improvement in Fibrosis or Nonalcoholic Steatohepatitis (NASH) at Week 24 — 30.6; 24.0; 26.5; 14.3 Percentage of Participants — p=0.055
Phase 2 N=118 Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis
Chronic Hepatitis C Infection
Primary: Safety of Fuzheng Huayu Treatment in Chronic Hepatitis C Subjects Who Have Failed Prior Anti-HCV Therapy or Cannot Receive or Refused Interferon Based Therapy. — 55; 55…
N/A N=34 Transient Elastography in Autoimmune Hepatitis
Liver Cirrhosis
Primary: Sensitivity and Specifity of Transient Elastography in Detection of Liver Cirrhosis — 0.83; 1.00; 1.00; 0.97 Probability
N/A N=171 Shear Wave Sonoelastography in Pediatric Liver Fibrosis
Sonoelastography · Elastography · Elastograms
Primary: 2D-SWE Measurements' Capability of Predicting Stages of Fibrosis Based on METAVIR Scoring System — NA; 96.9; 95.2; 1.00 percentage of exams
Phase 1 N=10 Magnetic Resonance Elastography for Assessment of Liver Fibrosis (MK-0000-132)(COMPLETED)
Liver Fibrosis · Hepatitis C Virus
Primary: Repeated Maximum Liver Elastic Stiffness (Kilopascal [kPa]) Measurements — 4.54; 4.64; 5.10; 5.14 kPa
N/A N=70 Velacur by Sonic Incytes for Portal Hypertension
Portal Hypertension · Chronic Advanced Liver Disease
Primary: Liver Stiffness Measurements for Participants With Compensated Advanced Chronic Liver Disease With and Without Esophageal Varices Upon Esophagogastroduodenoscopy (EGD)…
N/A N=84 Liver Fat Quantification by Magnetic Resonance Imaging (MRI) - Prediction of Postoperative Complications
Fatty Liver · Surgery
Primary: Percentage of Liver Fat Content on MRI in Patients With Serious Post-operative Complications (Clavien-Dindo Grade ≥IV) — 1.3; 13.6 Percentage of liver fat content
N/A N=55 Determination of Liver Stiffness in Chronic Liver Disease Patients by Acoustic Radiation Force Imaging (ARFI) Ultrasound
Chronic Liver Disease
Primary: Agreement in Measured Liver Stiffness Between ARFI and MRE — 3.21; 2.48; 1.81; 2.0 kPa
Phase 2 N=12 The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease
NAFLD · Nonalcoholic Fatty Liver · NASH - Nonalcoholic Steatohepatitis
Primary: Intrahepatic Lipid Content (IHL, Percent Liver Fat) — 3.9 absolute change in percentage liver fat — p=0.4
Phase 2 N=265 Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
Cirrhosis, Liver
Primary: Mean Change From Baseline in Liver Biopsy Immunohistochemical Marker of Hepatic Stellate Cell (HSC) Activation and Collagen Synthesis at Week 52 — 0.02065; 0.02819…
N/A N=51 Obesity and Nonalcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
Primary: Hepatic Insulin Sensitivity Index (HISI) — 0.8; 1.4 [10000/(μmol/min)x(mU/L)] — p=<0.019
Phase 2 N=30 Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
Nonalcoholic Steatohepatitis
Primary: Mean Change in Liver Fibrosis of Corrected T1 (cT1) Mapping (LiverMultiScan -LMS) — 19.15; 1.25 milliseconds (ms) — p=0.1621
Phase 2 N=25 Human Fetal Liver Cell Transplantation in Chronic Liver Failure
Liver Cirrhosis
Primary: Patient Survival — 5; 6; 4; 10 participants — p=0.4340
Phase 2 N=80 Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver · Nonalcoholic Steatohepatitis
Primary: Absolute Change in Intrahepatic Lipid Content, by 1H-MRS — -6.6; 3.6 Mean absolute percentage change
N/A N=63 A Study to Evaluate Liver Stiffness With Shear Wave Elastography
Chronic Liver Disease · Advanced Fibrosis · Advanced Cirrhosis
Primary: Median Endoscopic Ultrasound (EUS) Shear Wave Elastography — 0.11 kPA
Phase 2 N=53 Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: Change in Intrahepatic Lipid Content Between Baseline and 6 Months as Measured by 1H-magnetic Resonance Spectroscopy (1H-MRS). Endpoints Were Assessed at Baseline and 6…
Phase 2 N=155 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
Hepatic Cirrhosis · Liver Fibrosis · Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 48 — 28.2; 24.3; 28.2…
N/A N=21 Stage 3 Fontan Operation Liver Ultrasound Study
Fontan Operation
Primary: Shear Wave Speed (Liver Stiffness) — 1.18; 2.28; 2.22; 2.08 meters per second — p=<0.0001
N/A N=30 Beyond Confounders: Addressing Source of Measurement Variability and Error in Shear Wave Elastography
Liver Fibrosis · Liver Diseases
Primary: Deviations From Suggested Guidelines- Any Effect on Agreement — 0.77; 0.75; 0.69; 0.86 correlation coefficient
N/A N=14 Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric Surgery
NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease
Primary: Percent Change in Liver Fat Between Baseline and 12 Weeks Post-surgery — -16.4 percent change
Phase 2 N=18 Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis
Liver Fibrosis · Hepatitis C · HIV
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events — 100; 100; 100 percentage of participants